Sugemalimab

舒格利单抗

Report date: 2025/03/26 15:58:02

Base Information

Drug NameSugemalimab
Drug Alias NameRecombinant human anti-PDL1 monoclonal antibody (CStone Pharmaceuticals)SugelimabZegemaZegemetZegemex +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[23] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2021/12/20
Country/TerritoryUnited StatesAustraliaUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCstone Pharmaceuticals (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAbdul Latif Jameel HealthPfizer IncCstone Pharmaceuticals +[9] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[21] 
Inactive IndicationsAdenocarcinomaNeoplasms

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG